For the second-straight year and third time in five years, the Dow, S&P 500, and Nasdaq started off the calendar with quarterly losses. ‘Didn't get off the bus,' is the apt sports colloquial that comes to mind.

Revolve Wealth Partners LLC lowered its position in shares of Colgate-Palmolive Company (NYSE: CL) by 34.5% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 16,022 shares of the company's stock after selling 8,452 shares during the quarter. Revolve Wealth Partners LLC's

Ascent Group LLC raised its holdings in shares of Colgate-Palmolive Company (NYSE: CL) by 19.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 36,321 shares of the company's stock after purchasing an additional 5,906 shares during the period.

Braun Stacey Associates Inc. trimmed its holdings in shares of Colgate-Palmolive Company (NYSE: CL) by 4.0% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 223,790 shares of the company's stock after selling 9,343 shares during the quarter. Braun Stacey Associates

Investors looking for stocks in the Consumer Products - Staples sector might want to consider either Ahold NV (ADRNY) or Colgate-Palmolive (CL). But which of these two stocks is more attractive to value investors?

CL's Hill's Pet Nutrition outperforms a soft market as prescription diets, cat growth and science-led innovation drove share gains and sustained momentum.

Colgate-Palmolive expects to drive growth in North America this year, in part with new versions of products in oral and skin care.

Brookstone Capital Management raised its stake in Colgate-Palmolive Company (NYSE: CL) by 11.1% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 158,730 shares of the company's stock after purchasing an additional 15,842 shares during the period. Brookstone Capital

Colgate-Palmolive (NYSE:CL) lost a key Wall Street backer on Tuesday as TD Cowen analyst Robert Moskow downgraded the stock from Buy to Hold and cut his price target to $85 from $96, citing surging oil-based input costs tied to the Iran War.

Colgate-Palmolive's recent decline has the stock squarely in correction territory. The recent 13.6% drop in just a month may be a case of too much too fast.